Centogene's frontotemporal dementia (ftd) genetic study, efront, reaches initial patient enrollment milestone

Cambridge, mass. and rostock, germany, and berlin, dec. 13, 2023 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the company reached its initial recruitment and genetic testing milestone in the observational efront study, being conducted to advance the genetic understanding of frontotemporal dementia (ftd).
CNTG Ratings Summary
CNTG Quant Ranking